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Abstract
Background: Matrix protein 2 (M2) is an integral tetrameric membrane protein of influenza A
virus (IAV). Its ectodomain (M2e) shows remarkably little diversity amongst human IAV strains. As
M2e-specific antibodies (Abs) have been shown to reduce the severity of infection in animals, M2e
is being studied for its capability of providing protection against a broad range of IAV strains.
Presently, there is little information about the concentration of M2e-specific Abs in humans. Two
previous studies made use of ELISA and Western blot against M2e peptides and recombinant M2
protein as immunosorbents, respectively, and reported Ab titers to be low or undetectable. An
important caveat is that these assays may not have detected all Abs capable of binding to native
tetrameric M2e. Therefore, we developed an assay likely to detect all M2e tetramer-specific Abs.
Results: We generated a HeLa cell line that expressed full length tetrameric M2 (HeLa-M2) or
empty vector (HeLa-C10) under the control of the tetracycline response element. These cell lines
were then used in parallel as immunosorbents in ELISA. The assay was standardized and M2e-
specific Ab titers quantified by means of purified murine or chimeric (mouse variable regions,
human constant regions) M2e-specific Abs in the analysis of mouse and human sera, respectively.
We found that the cell-based ELISA was substantially more effective than immobilized M2e peptide
in detecting M2e-specific Abs in sera of mice that had recovered from repetitive IAV infections.
Still, titers remained low (< 5 µg/ml) even after two consecutive infections but increased to ~50
µg/ml after the third infection. Competition with free M2e peptide indicated that ~20% of M2e-
specific Abs engendered by infection reacted with M2e peptide. In humans presenting with naturally
acquired influenza virus infection, 11 of 24 paired sera showed a ≥ 4-fold increase in M2e-specific
Ab titer. The Ab response appeared to be of short duration as titers were very low (average 0.2
µg/ml) in all patients at onset of infection and in controls, in spite of evidence for previous exposure
to IAV.
Conclusion: The results provide convincing evidence that M2e-specific Ab-mediated protection
is currently lacking or suboptimal in humans.
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Background
Matrix protein 2 (M2) is a 97 aa-long transmembrane pro-
tein of IAV [1]. It contains a 24 aa-long (23 aa after post-
translational removal of the N-terminal Met) non-
glycosylated N-terminal ectodomain (M2e). The mature
protein forms homotetramers [2,3] that are displayed at
high density (~50% of density of hemagglutinin (HA)
trimers) in the plasma membrane of infected cells during
the stage of virus maturation [1,4] but at low density (1–
2% of HA) in the membrane of mature virus particles [5].
The protein exhibits pH-inducible proton transport activ-
ity and regulates the pH of the viral core during virus entry
into the host cell and of transport vesicles that deliver viral
transmembrane proteins to the plasma membrane for
virus assembly [6,7].
There has been growing interest in M2 as a "universal"
vaccine that may protect against a much wider range of
IAVs than current vaccines. The potential of M2 as "uni-
versal" vaccine derives from the following observations:
First, antibodies (Abs) directed against its ectodomain
(M2e) have been shown to restrict virus replication and
reduce severity of disease in animal models [4,8-18],
though they are less protective than HA-specific Abs and
cannot provide "sterilizing immunity" or clear an infec-
tion on their own [4]. Second, M2e shows a remarkably
high degree of structural conservation amongst human
IAV strains. This is demonstrated in Fig 1, which shows
the M2e aa composition of 1505 IAVs isolated from
humans between 1918 and 2005. Third, humans cur-
rently appear to lack M2e-specific Ab-mediated protec-
tion. This has been indicated by two studies that measured
M2 specific Ab titers in human sera. In one of these [19],
paired serum samples from the acute and convalescent
phase of 17 patients presenting with naturally acquired
influenza virus infection were tested by ELISA and West-
ern blot for Abs reactive with full-length M2 generated in
the baculovirus system. By ELISA, 5 (35%) convalescent
sera showed a rise of ≥ 2-fold in M2-specific and 15 (88%)
in nucleoprotein (NP)-specific Ab titer [19]. The Western
blot appeared to be more sensitive as it detected M2-spe-
cific Abs in 13 (70%) convalescent serum samples. Impor-
tantly, however, no M2-specific Abs could be detected in
acute serum samples, which was in marked contrast to
NP-specific Abs, which were detectable by ELISA and
apparently resulted from previous infections or vaccina-
tions (NP is a relatively conserved IAV protein). Similarly,
no significant differences in Ab titers could be detected
between sera from 66 patients with influenza and 44
influenza negative individuals when tested by ELISA
against M2e peptide immunosorbent [20]. Taken
together, these studies indicated that M2-specific Ab
responses were inconsistently and poorly induced in
humans by IAV infection and, if induced, appeared to be
of low titer and short duration. Similar findings were
made in mice, in which recovery from pulmonary infec-
tion also did not result in substantial M2e-specific Ab tit-
ers when measured by ELISA against M2e peptide
[10,11,13].
An important caveat with regard to the low/absent M2e-
specific Ab responses is the possibility that previously
used assays failed to detect the entire repertoire of M2e-
specific Abs. The main M2 immunogen generated in the
course of infection is presumably the native M2 homote-
tramer, but only a fraction of native tetramer-specific Abs
may react with denatured M2 protein in Western blot [19]
or monomeric M2e peptides coated onto plastic [20]. To
avoid this shortcoming, we previously used virus-infected
M2e sequence diversity amongst human influenza A virus iso- lates Figure 1
M2e sequence diversity amongst human influenza A 
virus isolates. The sequence of 1505 human isolates 
(records in public data banks on August 17, 2006) of H1N1, 
H1N2, H2N2, H3N2, H5N1 and H9N2 subtypes is repre-
sented as a percentage of the M2e consensus sequence, 
which is listed in single amino acid code on the left from top 
to bottom, excluding the postranslationally removed methio-
nine. Observed replacement mutations are listed on the right 
side by single amino acid code and their overall frequency is 
indicated by the gray portions of the horizontal bars.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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MDCK cells as immunosorbents to measure the M2e-spe-
cific Ab response in mice immunized with M2e-specific
vaccines [13]. However, because virus-infected cells
express a variety of IAV proteins, this assay could not be
used to measure M2e-specific Abs in sera from hosts that
have been exposed to IAV. Therefore, we generated an
adherent HeLa cell line that stably expressed full-length
tetrameric M2 under the control of the tetracycline
response element (Tet) and used it as an immunosorbent
in ELISA. We found that HeLa-M2 immunosorbents
detected higher Ab titers than M2e-peptide immunosorb-
ents in sera of mice immunized by IAV infection. The
results indicated that ~80% of the M2e-specific Abs
engendered by infection reacted exclusively with cell-
expressed (tetrameric) M2e. Still, M2e-specific Ab titers
remained low (< 5 µg/ml), even after two consecutive
infections, while NP-specific titers reached maximum lev-
els (50–100 µg/ml) after the first infection. Measurement
of M2e-specific Ab titers in paired serum samples from the
acute and convalescent phase of humans presenting with
natural IAV infection revealed a very low M2e-specific Ab
titer (average 0.2 µg/ml) in acute serum samples and a ≥
4-fold increase in only 50% of the patients. Taken
together, the results confirmed the generally poor induc-
tion of the M2e-specific Ab response by IAV infection and
indicated that humans currently lack optimal M2e-spe-
cific protection. This provides an important reason for
development of an M2e-specific vaccine.
Results
Development of the HeLa-M2 ELISA
M2-specific Ab responses have been measured previously
by assays that used extracts of cells infected with M2-
recombinant baculovirus [19] or M2e-peptides and pep-
tide conjugates as immunosorbents [10,13,14,20]. These
immunosorbents may not detect the entire repertoire of
Abs capable of reacting with native tetrameric M2e dis-
played in the plasma membrane of infected host cells. We
therefore decided to develop an ELISA that used an M2-
transfected adherent cell line as immunosorbent. Trans-
fection of various types of target cells with an expression
vector encoding the full-length PR8-M2-GFP fusion pro-
tein resulted in good transient expression but generation
of a stable transfected cell line consistently failed (data not
shown). We suspected that this failure may be the conse-
quence of an inhibitory effect of M2 expression on cell
metabolism or growth, as has been suggested by other
investigators [21]. Culture of transfected cells in the pres-
ence of the M2 inhibitor amantadine did not improve
selection of stable transfectants, which is in agreement
with the fact that PR8 is resistant to this inhibitor [5]. We
then turned to the "Tet-on" expression system, in which
M2 is under the control of the minimal CMV promoter
and tetracycline response element. In this system, the con-
stitutive expression of the inserted transgene is minimal
but can be increased by addition of tetracycline or doxycy-
cline to the culture medium. Stable M2-transfectants
could be selected in this controlled expression system.
Although the selected HeLa-M2 line turned out to be quite
leaky for M2 expression in the absence of doxycycline
(Figure 2A), it could nevertheless be propagated in long-
term culture and M2 expression could be further
enhanced by treatment of the cells for two days with dox-
ycycline (1 µg/ml) prior to their use as immunosorbents
in ELISA (Figure 2A). To control for non-specific Ab bind-
ing in the ELISA, we also generated a HeLa cell line (HeLa-
C10) that was stably transfected with empty vector.
Cellular immunosorbents were prepared in flat bottom
96-well polystyrene plates as described in the Method sec-
tion. The cells were cultured for 2 days in the presence of
doxycycline and then fixed for 20 min with 0.05% glutar-
aldehyde and stored in the refrigerator with PBSN-1% BSA
medium until used for assay. The plates could be stored
for several weeks without major loss of antigenic activity
(Figure 2B). Glutaraldehyde-fixed HeLa cells exhibited a
Antigenicity of HeLa-M2 cells Figure 2
Antigenicity of HeLa-M2 cells. A. HeLa-M2 cell immuno-
sorbents were prepared in medium without (diamonds) or 
with (circles) doxycycline (1 µg/ml) and tested for reaction 
with the M2e-specific MAb 14C2-S1-4 (filled symbols) or 
HA-specific MAb H36-4-5.2 (open symbols). Bound MAb was 
detected by ELISA as described in the Method section. Sym-
bols indicate mean OD(490–750) of triplicates. B. HeLa-M2 
immunosorbent plates were prepared as described in the 
Method section. Plates, stored for different lengths of time in 
the refrigerator, were tested in ELISA with M2e-specific MAb 
14C2-S1-4. Three independent assays, each indicated with a 
distinct symbol, were performed with distinct sets of HeLa-
M2 plates that differed in storage time. In each assay, the sat-
uration binding (OD) of the MAb was determined and 
expressed as a percentage of the plate with the highest satu-
ration binding (defined as 100%) seen in the given assay. Lin-
ear regression analysis of the data indicated a relation of y = -
0.46x +100 between antigenic activity (y) and days of storage 
(x) at 4–7°C.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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high endogenous alkaline phosphatase activity that could
not be inhibited by levamisol (data not shown) but a low
endogenous peroxidase activity. This made the use of a
peroxidase-based ELISA system highly preferable.
As judged by ELISA against HeLa-C10 immunosorbent,
sera showed substantial and individually distinct back-
ground binding in the HeLa ELISA. Therefore, each serum
was routinely tested in parallel on HeLa-M2 and HeLa-
C10 immunosorbents, which were both present on the
same assay plate (Fig 3A–C). M2-specific binding activity
was then computed as the difference in OD (∆ OD)
between HeLa-M2 and HeLa-C10 immunosorbents and
used to estimate the M2e-specific Ab concentration by
comparison to the titration curve generated with purified
M2e-specific MAb 14C2-S1-4. The suitability of this
method for quantification of M2e-specific Ab titers was
tested with artificial mixtures of MAb 14C2-S1-4 and
naive mouse serum (NMS). As shown in Fig 3, specific
binding was increasingly suppressed by increasing serum
concentration. Nevertheless, 0.1 µg of MAb in 20% NMS
(corresponding to 0.5 µg MAb/ml neat serum) could be
reasonably well quantified as long as the quantification
was based only on ∆ODs seen at the trailing edge of the
titration curve (Fig 3C). Because of this inhibitory effect,
sera were tested at concentrations of ≤ 1/10. Given an
assay-sensitivity of ~10 ng/ml, the threshold of M2e-spe-
cific Ab detection in sera was ~0.1 µg/ml.
To determine whether M2 was expressed in HeLa cells as
tetramers, cell monolayers were fixed for 20 min with glu-
taraldehyde (bivalent cross-linking fixative) or left
unfixed. The cells were then solubilized, the extracts sub-
jected to SDS PAGE under non-reducing conditions, blot-
ted onto a PVDF membrane and analyzed with M2e-
specific MAb (Fig 4A). Without fixation, the main molec-
ular species detected in extracts of HeLa-M2 cells were
monomeric (~13 kDa), dimeric (~24 kDa), and a faint
band of tetrameric (~45 kDa) M2. The tetrameric species
was more prominent in extracts of glutaraldehyde-fixed
cells, which additionally showed a band corresponding to
a trimer (~36 kDa). These findings are consistent with
observations made by other investigators [2,3] and indi-
cated that HeLa-M2 cells expressed M2 in tetrameric form.
As expected, no M2-specific bands were detected in
extracts of HeLa-C10 cells. Judging from the titration
curves generated with M2e-specific MAbs (Fig 4B) and
sera from M2e-MAP-immunized mice (Fig 4C), doxy-
cyline-induced HeLa-M2 cells expressed more M2 than
MDCK cells 8–11 hrs after infection with ~10 TCID50 of
IAV/cell and were more effective in detecting M2e-specific
Abs than infected MDCK cells.
Taken together, the results showed that HeLa-M2 cells
expressed tetrameric M2 and, following glutaraldehyde
fixation, formed sensitive immunosorbents that were
quite stable over several weeks of storage at 4°C.
HeLa-M2 cells are more effective than M2e peptide 
immunosorbents in detecting M2e-specific Abs in sera of 
infection-immunized mice
Because most previous studies used peptide immunosorb-
ents for measurement of M2e-specific Ab titers, we were
interested in comparing peptide and HeLa-M2 immuno-
sorbents for efficacy of M2e-specific Ab detection. To this
end, MAbs and serum pools from mice immunized by
infection or injection of M2e-MAP (M2e multiple anti-
genic peptide) [13] were tested in parallel for binding to
HeLa-M2 and M2e-peptide immunosorbents. The latter
had been prepared by coating wells of flat bottom polysty-
rene plates (same as used for preparation of HeLa-M2
Effect of serum concentration on the HeLa-M2 ELISA Figure 3
Effect of serum concentration on the HeLa-M2 
ELISA. Preparations of MAb 14C2-S1-4 at 0.1 µg/ml in dilu-
ents containing various concentrations (0, 5, 10, 20%, A-D) 
of NMS were tested in ELISA for binding to HeLa-M2 (filled 
circle) and HeLa-C10 (open circle). The difference in OD (∆ 
OD) between HeLa-M2 and HeLa-C10 is plotted in red. ∆ 
OD was subsequently used to estimate the concentration of 
M2e-specific Ab in serum-containing preparations. The sym-
bols show means of triplicates ± SEM. A representative 
example of several independent experiments is shown, in 
which different NMS samples and MAb concentrations were 
tested.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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immunodsorbents) with M2e-MAP at various concentra-
tions. OD values increased with increasing concentration
of coating peptide. The most informative results were
obtained at the coating concentration of 0.2 µg/ml and
are shown in Fig 5. At this coating concentration, all M2e-
specific MAbs, except M2-1, reacted better with M2e pep-
tide than with HeLa-M2 cells (Fig 5A). Similarly, sera from
mice immunized with (4)M2e-MAP [13] reacted better
with M2e peptide than with HeLa-M2 (Fig 5B). By con-
trast, sera from mice immunized by consecutive infections
bound much better to HeLa-M2 than to M2e-MAP (Fig
5C). Thus, M2e-specific MAbs and Abs induced by immu-
nization with M2e-MAP differed in fine specificity and/or
avidity from those induced by infection.
A possible explanation for the stronger reaction of sera
from infection-immunized mice with HeLa-M2 than M2e
peptide immunosorbents was that infection induced Abs
to the intracytoplasmic region of M2 (in addition to M2e)
and the former Abs may be detected by HeLa-M2 immu-
nosorbents even though the cells had not been permeabi-
lized intentionally. This possibility was tested with an
antiserum specific for the C-terminus of M2. As shown in
Fig 6A, this antiserum reacted with intentionally permea-
bilized but not with the standard HeLa-M2 immunosorb-
ent, while M2e-specific MAbs, as expected, reacted equally
well with both. Thus, without permeabilization, the
HeLa-M2 ELISA appeared to detect exclusively M2e-spe-
cific Abs. This conclusion was confirmed by showing that
sera from infection-immunized mice failed to react with
HeLa-M2 immunosorbents that had been treated with
trypsin to remove a major portion of M2e and thereby
destroyed its antigenicity (Fig 6B).
Taken together, the results suggested that sera from infec-
tion-immunized mice contained M2e-specific Abs
directed against conformational determinants displayed
by tetrameric M2e but not monomeric M2e peptide. To
confirm this proposition, sera and MAbs were tested for
binding to HeLa-M2 in the presence of competing M2e
peptide. As shown in Fig 7, the binding of M2e-specific
MAbs and serum from M2e-MAP-immunized mice to
HeLa-M2 was completely inhibited by M2e(2–24) pep-
tide. By contrast, serum from infection-immunized mice
Form and density of M2 expression relative to PR8-infected MDCK cells Figure 4
Form and density of M2 expression relative to PR8-infected MDCK cells. A. Doxycycline-induced HeLa-M2 and 
HeLa-C10 cells, without (No) or with (Yes) prior glutaraldehyde fixation, were solubilized. Cell extracts were electrophoresed 
under non-reducing conditions, blotted onto a PVDF membrane and tested for presence of M2 by staining with MAb 14C2-S1-
4. MW shows the position of molecular weight markers. B. M2e-specific MAbs 14C2-S1-4 (squares) and M2-1 (triangles) were 
tested by ELISA for binding to HeLa-M2 (filled symbols), virus-infected MDCK cells (open symbols), nine hrs after infection 
with 10 TCID50 of PR8 per cell, and the corresponding control cell immunosorbents. Symbols show mean ± SEM of triplicate ∆ 
ODs. A representative assay of several independent repeat experiments is shown. C. Sera from mice immunized with M2e-
MAP were tested as in B for binding to HeLa-M2 (filled symbols) and PR8-infected MDCK cells (open symbols). Pooled sera 
from two different groups of mice (square, triangle) are shown. A representative assay of several independent experiments is 
shown.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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was only partially inhibited. The results indicated that
~20% of the M2e-specific Abs induced by infection
(pooled serum from four mice) recognized determinants
shared by M2e peptide and HeLa-M2 and ~80% recog-
nized determinants unique to HeLa-M2. The latter most
likely are conformational determinants of M2e-tetramers.
Analysis of M2e- and NP-specific Ab responses engendered 
in mice by infection
Sera from mice (2–5 mice/group) that had recovered from
one, two or three consecutive IAV infections were tested in
the HeLa-M2 ELISA. The results (Fig 8A) revealed low M2e
Ab titers three weeks after primary infection (GMT = 1.9
µg/ml, n = 4 groups). The titers increased slightly, though
not significantly, after recovery from a second infection by
a heterosubtypic IAV (GMT = 3.0 µg/ml, n = 7 groups) and
then rose significantly to 49 µg/ml (n = 2 groups of two
mice each) after the third infection. The same sera were
also tested for Abs directed to NP, a viral protein that is
highly conserved between IAV strains. In this case (Fig
8B), close to maximum NP-specific Ab titers (GMT = 43
µg/ml, n = 5 groups) were reached after recovery from the
first infection and the titers increased only slightly after a
second (GMT = 51 µg/ml) and third (GMT = 60 µg/ml)
infection. Thus, in spite of the improved assay, which
probably is capable of detecting all biologically relevant
M2e-specific Abs, the results indicated that infection
engendered a poor M2e-specific Ab response in mice and
that several consecutive infections were required to raise
the response to the level attained by NP-specific Abs after
a single infection.
Analysis of M2e- and NP-specific Ab responses in humans 
undergoing a natural IAV infection
Paired serum samples from the acute and convalescent
phase of 24 adults presenting with IAV infection and sera
from 5 controls were tested for M2e- and NP-specific Ab
titers. The assays were performed as for the measurement
of these Ab responses in mouse sera except for using i) dif-
ferent serum diluents that helped to reduce the high back-
ground binding of human sera (see method section) and
ii) a mixture of biotinylated goat-anti-human kappa- and
lambda-specific antisera for detection of bound Ab. The
M2e-specific Ab titers were expressed in µg/ml in relation
to chimeric M2e-specific MAb TRF-3.1. (Note that the dif-
ference in M2e sequence at aa position 21 between PR8
(Gly) and most contemporary human IAV strains (Glu)
has no known effect on M2e antigenicity). The results
showed that M2e-specific Ab titers were very low (or
undetectable at 1/20 serum dilution) in acute (GMT =
Comparison between HeLa-M2 and M2e-peptide immunosorbents Figure 5
Comparison between HeLa-M2 and M2e-peptide immunosorbents. A. Binding of MAbs to HeLa-M2 (filled symbols) 
and M2e-peptide immunosorbent (open symbols), formed by coating wells with 50 µl of M2e-MAP at 0.2 µg/ml. Two MAbs 
that exemplify the opposite extremes in binding activity of currently available M2e-specific MAbs, are shown: 14C2-S1-4 
(squares) and M2-1(triangles). Each symbol shows mean OD ± SEM of triplicates. B. M2-specific binding (∆ OD) against HeLa-
M2 (closed symbols) and M2e-MAP (open symbols) of two representative sera (triangle, square) from groups of mice immu-
nized by three inoculations with (4)M2e-MAP. C. As in B, except for using sera from mice that had been immunized by three 
consecutive pulmonary influenza virus infections. All assays were performed at least twice and a representative assay is shown.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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0.14 µg/ml, n = 24) and control sera (GMT = 0.26 µg/ml,
n = 5), i.e. were in the range of the assay sensitivity thresh-
old. The titers increased by ≥ 4-fold (6–120 fold, average
22 fold) in convalescent sera of 11 patients and by <4-fold
(0.2 – 3.8-fold, average 1.7) in convalescent sera of 13
patients (Fig 9). The average M2e-specific Ab titer in con-
valescent sera was 0.56 µg/ml, an increase of 4 fold over
the average titer in acute sera. These findings are generally
similar to those reported by Black and collaborators [19].
The same sera were tested for NP-specific Ab titers. How-
ever, as no chimeric NP-specific Ab was available for
quantification, these titers were simply expressed relative
to an acute serum sample (serum 12B), which displayed a
high NP-specific Ab titer and was assigned an arbitrary
concentration of 100. On average, the NP-specific titers
increased by only 2.5-fold between acute and convales-
cent phases and only 5 patients showed a ≥ 4-fold
increase. In Fig 9, the patients are grouped according to
their M2e-specific Ab response into the eleven high (Fig
9C) and thirteen low (Fig 9D) responders. It is evident
that the eleven high anti-M2e responders showed on aver-
age also a stronger NP-specific response (3.5-fold increase
between acute and convalescent phases) than the low
responders (1.9-fold increase). Although the M2e- and
NP-specific Ab titers in human sera could not be com-
pared directly, the NP-specific titers appeared to be sub-
stantially higher than the M2e-specific titers, similar to
what was seen in mice after the first and second infection
(Fig 8). This was indicated by the fact that the NP- and
M2-specific ELISAs showed similar sensitivity (within 3-
fold range) for detecting mouse MAbs (Fig 10A), yet
detected NP-specific Abs in human sera at ~1000-fold
higher dilution than M2-specific Abs (Fig 10B). Thus,
human sera appear to contain100-1000-fold higher NP-
than M2e-specific Ab titers, e.g. ~0.2 µg/ml anti-M2e and
20–100 µg/ml anti-NP.
Only M2e is accessible to Ab on fixed non-permeabilized  HeLa-M2 cells Figure 6
Only M2e is accessible to Ab on fixed non-permeabi-
lized HeLa-M2 cells. A. Control naive mouse serum 
(NMS), a mouse serum specific for the intracytoplasmic C 
terminus of M2 and M2e-specific MAb were tested for reac-
tion with fixed HeLa-M2 and HeLa-C10 cells with (filled bars) 
and without (open bars) permeabilization. Mean ∆ ODs of 
duplicates are shown. B. Fixed HeLa-M2 and HeLa-C10 
immunosorbents were treated with increasing concentra-
tions of trypsin (dilution of 2.5% is indicated) and then tested 
for reaction with a constant dose of M2e-specific MAb (trian-
gles) or pooled serum from infection-immunized mice 
(squares). Symbols show ∆ ODs (mean ± SEM of triplicates). 
One of two independent assays is shown.
Competition of Ab binding to HeLa-M2 by free M2e peptide Figure 7
Competition of Ab binding to HeLa-M2 by free M2e 
peptide. Increasing concentrations of M2e(2–24) peptide 
were tested for ability to inhibit the binding of a constant 
dose of MAbs 14C2-S1-4 (triangles pointing up) and M2-1 
(triangles pointing down) or pooled sera from mice immu-
nized by three consecutive infections (squares) or three 
injections of (4)M2e-MAP (circles). MAbs were tested at 1 
µg/ml and sera at 1/200 dilution. Ab binding in the presence 
of competing M2e peptide was expressed as percent of its 
binding (∆ OD) in the absence of competing peptide. The 
results show the composite of three independent assays, 
each performed in triplicate. Each symbol shows the mean ± 
SEM of nine replicates.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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Discussion
Previous studies indicated poor M2e-specific Ab
responses following IAV infection in mice [11,13] and
humans [19,20]. It was not clear, however, whether the
low responses reflected the inability of the previously
used assays to detect the entire repertoire of M2e-specific
Abs or whether the M2 presented to the immune system
in the context of an infection is poorly immunogenic. To
resolve this issue, we developed an ELISA that used M2-
transfected HeLa cells as immunosorbent. Assuming that
HeLa-cells expressed M2 in the same form as virus-
infected host cells, this cellular immunosorbent would be
expected to detect all biologically relevant M2-specific
Abs. HeLa-M2 cells were shown to express tetrameric M2
(Fig 4A) and were found to be superior to immobilized
M2e peptide immunosorbent in detecting M2e-specific
Abs induced in mice by repetitive infections (Fig 5C).
However, in spite of the improved assay, the HeLa-M2
ELISA reaffirmed that the M2e-specific Ab response was
poorly induced by infection. Thus, three consecutive
infections were required to raise M2e-specific Ab titers in
mice to the level (~50 µg/ml) reached in the NP-specific
response after a single infection (Fig 8). In humans, natu-
ral infection resulted in a ≥ 4-fold increase in M2e-specific
Ab titers in 45% of subjects. However, if induced, the
response appeared to be of short duration as M2e-specific
Ab titers were very low or undetectable in serum samples
obtained from the acute phase of the infection or from
controls. Thus, the study confirmed that IAV infection in
mouse and human induced a poor M2e-specific Ab
response and, more importantly, that humans lacked sig-
nificant M2e-specific Ab-mediated protection.
Competition binding studies indicated that ~20% of the
infection-induced M2e-specific Ab response (in a pooled
serum from four mice) that reacted with HeLa-M2 cells,
crossreacted with monomeric M2e-peptide. This is most
likely the fraction of the total response to native M2e-
tetramer that is detected by ELISA using M2e-peptide
immunosorbent and is induced by immunization with
M2e peptide vaccines that display M2e-peptides in mono-
meric form.
M2e- and NP-specific Ab responses of BALB/c mice convalescent  from primary, secondary and tertiary infection Figure 8
M2e- and NP-specific Ab responses of BALB/c mice con-
valescent from primary, secondary and tertiary infection. 
Sera from groups of BALB/c mice, obtained 3–5 weeks after 
recovery from primary, secondary or tertiary infection by hetero-
typic or heterosubtypic influenza A viruses, were tested by HeLa-
M2 ELISA for M2-specific Ab concentration. Each symbol shows 
the mean of at least two independent assays, each performed in 
triplicate or quadruplicate. Cross-bars indicate the geometric 
mean titer of all groups. B. The same sera were tested for NP-spe-
cific Ab titers by ELISA against purified NP.
M2e- and NP-specific Ab titers in human sera from the acute  and convalescent phase of naturally acquired influenza virus  infection Figure 9
M2e- and NP-specific Ab titers in human sera from the 
acute and convalescent phase of naturally acquired influ-
enza virus infection. A and B. Paired sera from the acute and 
convalescent phase of 24 patients were tested in ELISA against 
HeLa-M2. M2-specific Ab titers were quantified by comparison to 
the binding seen with purified M2e-specific mouse-human chimeric 
Ab TRF-3.1. A. Sera from 11 patients that showed a ≥ 4-fold 
increase in M2-specific Ab titer between acute and convalescent 
phase. Each line connects acute and convalescent titers of an indi-
vidual patient. B. Sera from 13 patients that showed <4-fold 
increase between acute and convalescent phase. The stipulated 
horizontal line in panels A and B indicate the threshold of detec-
tion. C and D. The same sera were tested in ELISA for NP-specific 
Ab titers. The titers are expressed relative to one convalescent 
serum sample with a high NP Ab titer, which was assigned an arbi-
trary value of 100. C and D show the acute and convalescent NP-
specific titers of the same patients shown in A and B, respectively.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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Although the majority (~80%) of infection-induced M2e-
specific Abs did not react with monomeric M2e-peptide,
none of the M2e-specific MAbs generated in our labora-
tory from infection-primed mice reacted exclusively with
M2 tetramer (data not shown). This can be explained by
the fact that all lymphocyte donor mice were boosted with
M2e-MAP prior to fusion – to increase the probability of
isolating M2e-specific hybridomas [13] – and initial
hybridoma cultures had to be screened for M2e-specific
Ab secretion by ELISA against M2e-peptide immunosorb-
ent as the HeLa-M2 cell line was not available at the time.
We are currently attempting to isolate M2e tetramer-spe-
cific hybridomas from infection-immunized mice with-
out peptide boost and using the HeLa-M2 ELISA for
screening. Holsinger and Lamb, 1991 [2] described an
MAb that reacted in Western blot with M2 dimer but not
M2-monomer and appears to be a member of this domi-
nant M2-polymer-specific Ab group.
The reason for the low M2e-specific Ab response induced
by infection remains unknown but the following two fac-
tors are likely to contribute. First, the number of naive
M2e-specific precursor B cells may be very small and their
expansion into a sufficiently large population of M2e-spe-
cific Ab-secreting and memory B cells may require several
rounds of stimulation. This is consistent with the finding
that three consecutive infections in mice were required for
induction of M2e-specific Ab titers in the range of 50 µg/
ml. It is consistent also with the small size of the antigenic
region of M2e. Indeed, the latter may comprise ≤ 15
amino acids [16,20,22], which is in the lower size range of
a typical protein epitope recognized by an individual Ab
[23]. The small size of the antigenic determinant would be
expected to restrict the number of unique combinations
of V gene segments that interact strongly with it and thus
the number of M2e-reactive B cells in the naive repertoire
[22]. Second, antigenic competition by the much more
numerous HA- and NA-specific B cells for a limited
amount of immunogenic entities may further suppress
the M2e-specific Ab response. To participate in a Th-
dependent Ab response, antigen-specific B cells must cap-
ture the specific antigen with their membrane Ig, internal-
ize and process it and finally display its associated helper
T cell determinants to permit cognate interaction with
activated helper T cells. As the immunogenic M2e entities
may consist predominantly of membrane fragments that
contain also associated HA and NA molecules, the much
more numerous HA- and NA-specific precursor B cells
would be expected to capture and consume most M2,
leaving little for stimulation of the few M2e-specific pre-
cursor B cells. Antigenic competition by HA-specific pre-
cursor B cells has been shown to suppress the NA-specific
Ab response both in humans [24] and mice [25]. The phe-
nomenon of antigenic competition was shown to depend
on the physical linkage between competing antigens [26,
27] and could be modified by prior immunization against
one of the component antigens [27, 28]. The fact that
good M2e-specific responses can be induced by immuni-
zation with isolated M2e antigen constructs supports a
role for antigenic competition in the low M2e-specific Ab
response. Still, assuming that most of the adult human
serum donors analyzed in this study had experienced sev-
eral previous IAV infections and in view of the sizeable
M2e-specific response seen in mice after three consecutive
infections (Fig 8), the low M2e-specific Ab titers in adult
human sera are nevertheless surprising. Perhaps induc-
tion of substantial and long lasting M2e-specific Ab
responses requires massive and consecutive pneumonias
as was the case in the experimental mice but may occur
only rarely in humans.
Conclusion
The study showed that on average only ~20% of the M2e-
specific Abs, generated in mice by repetitive IAV infections
and capable of binding to M2-transfected HeLa cells,
reacted also with monomeric M2e peptide. Use of the M2-
transfected HeLa cell-based ELISA for determination of
M2e-specific Ab titers in human sera convincingly showed
that M2e-specific Ab-mediated protection is currently sub-
Comparison between HeLa-M2 and NP ELISAs Figure 10
Comparison between HeLa-M2 and NP ELISAs. A. 
Purified murine MAbs 14C2-S1-4 (anti-M2e, closed circles) 
and L39-17 (anti-NP, open circles) were tested by ELISA for 
binding to HeLa-M2 and NP immunosorbents, respectively. 
Bound MAbs were detected in parallel assays by the same 
procedure (187-biotin/streptavidin-peroxidase/OPD). Each 
symbol shows mean OD ± SEM of triplicates. The data are 
representative of several independently performed assays. B. 
Five human control sera were tested at various dilutions in 
ELISA against HeLa-M2, NP and the corresponding control 
immunosorbents. Bound Abs were detected in parallel assays 
by the same procedure (biotinylated goat-anti-human cκ,λ/
streptavidin-peroxidase/OPD). M2-specific (closed symbols) 
and NP-specific binding (open symbols) are expressed as ∆ 
ODs. Symbols show means of duplicates. One of two inde-
pendent assays is shown.Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
Page 10 of 13
(page number not for citation purposes)
poptimal or absent in humans. This provides a strong
incentive for the development of an M2e-specific vaccine.
Methods
Media and solutions
ISC-CM is Iscove Dulbecco medium (Invitrogen) supple-
mented with 0.05 mM 2-mercaptoethanol, 0.005 mg/ml
transferrin (Sigma), 2 mM L-glutamine (Mediatech-Cell-
gro) and 0.05 mg/ml gentamicin (Mediatech-Cellgro).
ISC-CM was further supplemented with fetal calf serum
(FCS, Hyclone Laboratories) or bovine serum albumin
(BSA, Sigma) at the indicated concentrations. PFHM-II is
protein-free hybridoma medium (Invitrogen). TCRM is
phosphate-buffered (pH7.2) potassium/sodium saline
supplemented with 2.5 mM EDTA. PBSN is phosphate
buffered saline (pH7.2) supplemented with 3 mM NaN3.
Human and mouse sera
Acute and convalescent sera from humans were obtained
during an influenza therapeutic trial in the winter of
1985. Subjects were healthy young adults who presented
within 24 hours of onset of clinical influenza with fever (≥
100°F). Respiratory secretion samples from each subject
yielded influenza A (H3N2) virus and paired sera exhib-
ited a significant increase in hemagglutination-inhibiting
(HI) antibody between the acute and convalescent sam-
pling. Before submitting the sera for testing for M2e-spe-
cific antibody, the HI titers detected in a subset of the sera
were confirmed to be unchanged from the original titers.
Exempt status (EX2409036-1) for the measurement of Ab
titers in blinded paired sera from these studies was
granted by the Institutional Review Board of the Wistar
Institute,
Naive mouse serum (NMS) was obtained from BALB/c
mice. Pooled plasma or serum was obtained from conva-
lescent BALB/c mice (2–5 per group) 21–28 days after pri-
mary total respiratory tract infection with A/PR/8/
34(H1N1)-Mt.S-Wi (PR8), 10–28 days after secondary
and 7–37 days after tertiary infection. The viruses used for
consecutive infection shared the same M2e sequence but
differed in HA sequence to bypass extant HA-specific
immunity [13]. Plasma and serum were also obtained
from BALB/c mice that had been inoculated twice by the
intranasal or subcutaneous routes with the multiple anti-
genic peptide vaccine (4)M2e-MAP [13]. An antiserum
specific for the intracytoplasmic C terminus of M2 was
produced by immunization of mice with the linear pep-
tide T2M2C (AQYIKANSKFIGITEDADDGHFVSIELE, bio-
tech@voicenet.com), which contains on its N-terminus
the helper determinant of tetanus toxoid (830–843) [29]
and on its C terminus the intracytoplasmic C terminus of
M2 of PR8 (underlined in the linear peptide). Ten µg
T2M2C, 1 µg cholera toxin (Sigma) and 5 µg immunos-
timulatory oligodeoxynucleotide 1826 [30], emulsified in
100  µl PBS/50% incomplete Freund adjuvant, were
injected twice (3 week interval) into the tail base of five
BALB/c mice. Plasma was obtained three weeks after the
second injection and pooled. All protocols for animal
experiments were approved by the Animal Care and Use
Committee of the Wistar Institute.
Expression of M2 in HeLa Tet-on cells
Full-length M2 cDNA of PR8 was cloned into the BamHI/
EcoR V restriction site of pENTR™ TOPOR vector (Invitro-
gen) and the insert verified by sequence analysis. M2 was
subsequently cloned into the BamHI/EcoR V site of the
Tet-on response vector pTRE2pur (BD Biosciences) to pro-
duce pTRE2pur-M2. A HeLa cell line, stably transfected
with the pTet-On regulatory plasmid (BD Biosciences),
was maintained in ISC-CM supplemented with 10% Tet
system approved FBS (Tet-FBS) (BD Biosciences) and 500
µg/ml G418. For transfection, 105 Tet-On HeLa cells per
ml OptiMem medium were seeded into wells of a 6-well
plate and transfected with 4 µg pTRE2pur-M2 using Lipo-
fectamine 2000 (Invitrogen) according to the manufac-
turer's instructions. After 24 hrs, the cells were
resuspended in ISC-CM supplemented with 10% Tet-FBS
and 0.5 µg/ml puromycin (BD Biosciences), transferred
into 100 × 20 mm petri dishes and maintained in an air/
CO2 incubator for 2 weeks. Forty well-growing colonies of
adherent HeLa cells were harvested by overlaying individ-
ual, well separated, colonies with cloning discs (PGC Sci-
entific) soaked with trypsin-versene medium (Sigma) and
transferring the disks with adherent cells to individual cul-
ture dishes. Replicate samples of individual colonies were
seeded into 96-well plates, cultured for 2 days in ISC-CM-
10%FCS supplemented with doxycycline (1 µg/ml, BD
Biosciences) and then tested by ELISA for expression of
M2. The colony with the highest expression level of M2
was selected and expanded in ISC-CM supplemented with
10% Tet-FBS, 0.5 µg/ml puromycin and 500 µg/ml G418.
The cell line is reported here as HeLa-M2. A control HeLa
cell line stably transfected with empty pTRE2pur was sim-
ilarly generated and a clone (HeLa-C10) selected based on
good growth rate in the presence of the selection marker
puromycin.
ELISA using HeLa-M2 and HeLa-C10 cells
Cells were released from confluent monolayers in T75
flasks by incubation with TCRM and vigorous tapping of
the flask. Released cells were suspended at 105/ml in ISC-
CM supplemented with 10% FBS and 1 µg/ml doxycycline
and dispensed (150 µl/well) into flat bottom 96-well
Microtest™ plates (Falcon). After 2 days of incubation at
37°C in air/CO2, when the cells had formed closed mon-
olayers, the medium was flicked out and the monolayers
were fixed by incubation for 20 min at room temperature
with 100 µl 0.05% glutaraldehyde in PBS. The glutarade-
hyde was then flicked out, the monolayers washed withVirology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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PBSN and incubated with PBSN-1% BSA (~150 µl/well)
for blocking and storage of the plates in the refrigerator.
For ELISA, plates were washed once with PBSN and then
sequentially incubated with serum dilutions, biotinylated
rat anti-mouse Cκ-specific MAb 187 (ATCC HB58) or a
mixture of goat-anti-human Cκ and Cλ-specific antisera
(Southern Biotech), streptavidin-peroxidase polymer
(Sigma) and o-phenylenediamine dihydrochloride (OPD,
Sigma). Sera were diluted in PBSN containing 0.5% gela-
tin (Sigma) and 0.5% skim milk and tested in triplicate or
quadruplicate aliquots at 50 µl/well. Reagents were
diluted in PBSN-1% BSA and used at 50 µl/well except for
OPD, which was diluted in Sigma Fast buffer and used at
100 µl/well. All washes between sample applications were
done with PBSN. The assay was stopped by addition of 50
µl 2 M HCl/well and OD read with the Emax microplate
reader (Molecular Devices, Sunnyvale, CA) at 490 and
750 nm and the difference (OD490–750) recorded. Assays
were performed in parallel on HeLa-M2 and HeLa-C10
immunosorbents, both present in the same assay plate,
and the difference in OD490–750 between HeLa-M2 and
HeLa-C10 computed and recorded as ∆OD. This was nec-
essary because sera, particularly when used at low dilu-
tion, displayed substantial and individually distinct levels
of background binding as revealed by reaction with HeLa-
C10 (background binding was lower when the assay was
developed with IgG heavy chain-specific Ab reagents, pre-
sumably because Abs of IgM isotype make a dominant
contribution to assay background). Assays of murine and
human sera were quantified by titration of known con-
centrations of purified M2e-specific MAb 14C2-S1-4 and
the human-mouse chimeric MAb TRF-3.1 (see below),
respectively. Data were analyzed with the Softmax soft-
ware (Molecular Devices).
Competitive binding assay
The assay was essentially performed as described by
Zhang et al., 2006 [22], except for using HeLa cell immu-
nosorbents instead of M2e-peptide immunosorbents. In
brief, dilutions of M2e-peptide were mixed with a con-
stant dose of serum or MAb, incubated for 45 min and
then transferred to HeLa-M2 and HeLa-C10 immunosorb-
ents. After 45 min incubation, samples were removed and
bound Ab detected as in the HeLa ELISA described above.
The competing peptide was (2)M2e-MAP, which contains
2 chains of M2e(2–24) attached to a linear Cys-Gly-(Lys-
Gly)4-Ala backbone [13].
Trypsin treatment and permeabilization of HeLa 
immunosorbents
Glutaraldehyde-fixed and BSA-blocked HeLa cell monol-
ayers were extensively washed with warm (37°C) PBS and
then incubated for 30 min at 37°C with dilutions of
trypsin (2.5%, Gibco) in PBS ranging in 2-fold steps from
1/8 to 1/64. The trypsin was then rinsed off and the
immunosorbents were compared by ELISA to untreated
HeLa cell monolayers for binding of a saturating dose of
M2e-specific MAb or mouse antiserum raised against
T2M2C, which contained Abs specific for the intracyto-
plasmic C-terminus of M2. Glutaraldehyde-fixed and
BSA-blocked HeLa-M2 immunosorbents were permeabi-
lized by incubation for 10 min at room temperature with
PBSN containing 0.5% NP40. Detergent was then rinsed
off and the plates were used in ELISA as described above.
Analysis of HeLa-M2 by SDS PAGE and Western blot
HeLa-M2 and HeLa-C10 cell monolayers were cultured
for 2 days in 6-well cluster plates as described above for
preparation of ELISA plates but using 2 ml cell suspen-
sion/well. Monolayers were fixed with glutaraldehyde or
left unfixed. Monolayers were incubated with 0.5 ml lysis
buffer, the lysate was sonicated and electrophoresed
under non-reducing conditions in a preformed 10% Tris-
Bis polyacrylamide gel (NuPage, Invitrogen) with MES
running buffer. The gel was blotted onto a PVDF mem-
brane (Invitrogen). The membrane was blocked with
PBSN-1%BSA and stained by sequential incubation with
M2e-specific MAb 14C2, biotinylated anti-Cκ MAb 187,
streptavidin-peroxidase and diaminobenzidine.
Expression and purification of recombinant nucleoprotein 
(rNP)
Full-length NP cDNA of PR8 with 5' EcoRI and 3' NotI
restriction sites was inserted into the EcoRI/NotI site of
pFast Bac1 HTA vector (Invitrogen), which will encode NP
with N-terminal 6xHis tag and intervening TEV recogni-
tion site for subsequent enzymatic removal of the His tag.
Recombinant baculovirus expressing full-length NP was
generated and grown in Sf9 cells. rNP was isolated from
infected Sf9 cell lysates using the Y-PER™ 6xHis Column
Purification Kit (Pierce) according to the manufacturer's
instructions. Purified rNP was quantified by BioRad pro-
tein assay and light absorption at 280 nm.
NP-specific ELISA
Purified rNP (with 6xHis tag) was diluted to 5 µg/ml in
0.02 M NaCl and 25 µl samples were dispensed into 96-
well round bottom Serocluster™ polyvinyl plates. The
plates were covered with plastic sheets to avoid evapora-
tion, incubated overnight at room temperature and then
blocked for 1 hr by incubation with PBSN-1% BSA before
use in ELISA. The ELISA procedure was as indicated above
for the HeLa ELISA except that 25 µl volumes were used
for serum dilutions and reagents and 50 µl for substrate.
All samples were tested in parallel against wells coated
with rNP and against uncoated BSA-blocked control wells
and ∆ODs were computed. In the case of human sera,
binding activity was expressed relative to serum 12B,
which was included as standard in each assay and wasVirology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
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assigned an arbitrary NP-specific Ab concentration of 100.
In the case of mouse sera, binding activity was expressed
relative to purified NP-specific MAb L39-17.
M2e-peptide-specific ELISA
The multiple antigenic peptide consisting of a Cys-(Gly-
Lys)3-Ala backbone with two attached M2e(2–24) pep-
tides was used to coat wells of 96-well Microtest™ plates
(Falcon) by incubation of 50 µl peptide dilution in 0.02
M NaCl overnight at room temperature. The ELISA was
performed as described above for the HeLa-M2 assay.
Generation of M2e-specific chimeric mouse-human MAb
Cloning of light (L) and heavy (H) chain variable (V)
regions of the M2e-specific MAb M2-56, including signal
sequences, into the TOPO TA vector (Invitrogen) has been
described [22]. VL cDNA was amplified with Taq DNA
polymerase (Promega) using a forward primer that
hybridized to the leader sequence of the VL region and
contained a Kozak recognition site and EcoR V restriction
site 5' of the initiation codon (5' GGGGAT ATCCCACC
ATGGAGT CACAGA CTCAG 3'; EcoR V site underlined
and initiation codon in bold letters) and a reverse primer
that hybridized to the Jκ 1 region and contained a Sal I
restriction site (5' GTAAGTCGACTTACGTTTGATTTC-
CAGCTTGGTGCC 3'; restriction site underlined, terminal
Jκ 1 codon in bold, intervening sequence to provide cor-
rect splice site). The PCR product was inserted into the
TOPO TA vector and the cloned insert confirmed by EcoR
I digestion and sequencing. The TOPO TA vector was then
digested with EcoR V and Sal I restriction enzymes (NEB),
the VL fragment purified by agarose gel electrophoresis
and ligated with T4 DNA ligase (NEB) into the EcoR V/Sal
I site of the expression vector pAG4622 [31]. The ligation
reaction was transformed into E.coli HB101 competent
cells (Promega). Ampicillin-resistant colonies were
selected on LB agar and amplified in LB/ampicillin
medium. Plasmid was extracted with the Qiagen miniprep
kit and screened for presence of an insert of correct size by
digestion with EcoR V and Sal I and agarose gel electro-
phoresis. Inserts of selected clones were confirmed by
sequence analysis. The resulting expression vector was
designated pAG-LK56.1. A similar procedure was fol-
lowed for cloning of VH  into the expression vector
pAZ6860 [31]. VH was amplified with the forward leader
sequence primer (5' GGGGATATC CCACC ATGGGTT-
GGAGCTGTATCATC 3'; 5' flanking EcoRV site under-
lined) and the reverse JH3 primer (5'
GTAGCTAGCTGCAGAGACAGTGACCCAGAGT 3'; Nhe I
restriction site underlined and last 3' JH3 codon in bold).
The PCR product was purified, digested with EcoR V and
Nhe I and ligated into the EcoR V/Nhe I site of expression
vector pAZ6860. This resulted in the expression vector
pAZ-LH56. 106 X63-Ag8.653 cells [32] in OptiMem were
transfected with pAG-LK56.1 and pAZ-LH56 using Fugene
6 (Roche) according to the manufacturer's protocol. The
cells were cultured for 2–3 days in OptiMem with 10%
FCS and subsequently in medium supplemented with the
selection marker zeocin (1 mg/ml). After 2 weeks, residual
viable cells were cloned in the same medium by limiting
dilution. Medium from well growing clones was tested by
ELISA for concentration of M2e-specific Ab, using bioti-
nylated goat-anti-human Cκ-specific antiserum for detec-
tion of bound Ab. The clone with highest secretion of
M2e-specific MAb (TRF-3.1) was selected.
Purification of chimeric M2e-specific MAb
TRF-3.1 cells were expanded in ISC-CM supplemented
with 5% FCS and Zeocin (1 mg/ml). Cells from dense cul-
tures were pelleted and cultured to exhaustion (~90% cell
death) in protein-free PFHM-II medium without zeocin.
Cells and debris were pelleted, and chimeric MAb was
purified from the medium by adsorption to and elution
from a protein G column (Pierce).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JF generated the M2-transfected and control HeLa cell
lines and cloned viral NP for expression in the Baculovirus
system. MZ generated the chimeric (mouse/human) M2e-
specific H and L chain expression vectors and established
the chimeric Ab-secreting cell line. KM performed Western
blots and ELISAs. DZ participated in the performance of
ELISAs. HH expressed NP in the Baculovirus system. WW
contributed to the NP expression and editing of the man-
uscript. RBC collected the human sera and contributed to
the editing of the manuscript. WG designed the study,
established the cell-based ELISA and was involved in data
analyses and preparation of the manuscript.
Acknowledgements
This study was supported by NIAID grant AI46457 (WG) and contract 
NO1-AI-30039 (RBC) and the Commonwealth Universal Research 
Enhancement Program, Pennsylvania Department of Health. We are thank-
ful to Sherrie Morrison for providing us with the human light and heavy 
chain constant region expression plasmids and to Natasha Levenkova of the 
Wistar Institute's Bioinformatics core facility for developing a program to 
analyze M2e sequences deposited in public data banks.
References
1. Lamb RA, Zebedee SL, Richardson CD: Influenza virus M2 protein
is an integral membrane protein expressed on the infected-
cell surface.  Cell 1985, 40(3):627-633.
2. Holsinger LJ, Lamb RA: Influenza virus M2 integral membrane
protein is a homotetramer stabilized by formation of
disulfide bonds.  Virology 1991, 183(1):32-43.
3. Sugrue RJ, Hay AJ: Structural characteristics of the M2 protein
of influenza A viruses: evidence that it forms a tetrameric
channel.  Virology 1991, 180(2):617-624.
4. Mozdzanowska K, Maiese K, Furchner M, Gerhard W: Treatment
of influenza virus-infected SCID mice with nonneutralizingPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2006, 3:102 http://www.virologyj.com/content/3/1/102
Page 13 of 13
(page number not for citation purposes)
antibodies specific for the transmembrane proteins matrix 2
and neuraminidase reduces the pulmonary virus titer but
fails to clear the infection.  Virology 1999, 254(1):138-146.
5. Zebedee SL, Lamb RA: Influenza A virus M2 protein: mono-
clonal antibody restriction of virus growth and detection of
M2 in virions.  J Virol 1988, 62(8):2762-2772.
6. Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has
ion channel activity.  Cell 1992, 69(3):517-528.
7. Sugrue RJ, Bahadur G, Zambon MC, Hall-Smith M, Douglas AR, Hay
AJ: Specific structural alteration of the influenza haemagglu-
tinin by amantadine.  Embo J 1990, 9(11):3469-3476.
8. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP: Antibody
response to the M2 protein of influenza A virus expressed in
insect cells.  J Gen Virol 1993, 74 ( Pt 1):143-146.
9. Liu W, Li H, Chen YH: N-terminus of M2 protein could induce
antibodies with inhibitory activity against influenza virus rep-
lication.  FEMS Immunol Med Microbiol 2003, 35(2):141-146.
10. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr., Ger-
hard W: Induction of influenza type A virus-specific resistance
by immunization of mice with a synthetic multiple antigenic
peptide vaccine that contains ectodomains of matrix protein
2.  Vaccine 2003, 21(19-20):2616-2626.
11. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A,
Resch S, Fiers W: Universal influenza A vaccine: optimization
of M2-based constructs.  Virology 2005, 337(1):149-161.
12. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W:
A universal influenza A vaccine based on the extracellular
domain of the M2 protein.  Nat Med 1999, 5(10):1157-1163.
13. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu
TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon
Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver
JW: Preclinical study of influenza virus A M2 peptide conju-
gate vaccines in mice, ferrets, and rhesus monkeys.  Vaccine
2004, 22(23-24):2993-3003.
14. Black RA, Rota PA, Gorodkova N, Cramer A, Klenk HD, Kendal AP:
Production of the M2 protein of influenza A virus in insect
cells is enhanced in the presence of amantadine.  J Gen Virol
1993, 74 ( Pt 8):1673-1677.
15. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ:
Protection of mice against influenza A virus challenge by
vaccination with baculovirus-expressed M2 protein.  Vaccine
1995, 13(15):1399-1402.
16. Zhang M, Zharikova D, Mozdzanowska K, Otvos L, Gerhard W: Fine
specificity and sequence of antibodies directed against the
ectodomain of matrix protein 2 of influenza A virus.  Mol
Immunol 2006, 43(14):2195-2206.
17. Padlan EA: X-ray crystallography of antibodies.  Adv Protein Chem
1996, 49:57-133.
18. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr., Ogra PL:
Immunologic response to the influenza virus neuraminidase
is influenced by prior experience with the associated viral
hemagglutinin. I. Studies in human vaccinees.  J Immunol 1987,
138(9):3010-3013.
19. Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED:
Immunologic response to influenza virus neuraminidase is
influenced by prior experience with the associated viral
hemagglutinin. II. Sequential infection of mice simulates
human experience.  J Immunol 1987, 139(6):2010-2014.
20. Johansson BE, Kilbourne ED: Dissociation of influenza virus
hemagglutinin and neuraminidase eliminates their intraviri-
onic antigenic competition.  J Virol 1993, 67(10):5721-5723.
21. Schutze MP, Deriaud E, Przewlocki G, LeClerc C: Carrier-induced
epitopic suppression is initiated through clonal dominance.  J
Immunol 1989, 142(8):2635-2640.
22. Johansson BE, Kilbourne ED: Immunization with purified N1 and
N2 influenza virus neuraminidases demonstrates cross-reac-
tivity without antigenic competition.  Proc Natl Acad Sci U S A
1994, 91(6):2358-2361.
23. Demotz S, Barbey C, Corradin G, Amoroso A, Lanzavecchia A: The
set of naturally processed peptides displayed by DR mole-
cules is tuned by polymorphism of residue 86.  Eur J Immunol
1993, 23(2):425-432.
24. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto
I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL,
Krieg AM: Delineation of a CpG phosphorothioate oligodeox-
ynucleotide for activating primate immune responses in
vitro and in vivo.  J Immunol 2000, 164(3):1617-1624.
25. Coloma MJ, Hastings A, Wims LA, Morrison SL: Novel vectors for
the expression of antibody molecules using variable regions
generated by polymerase chain reaction.  J Immunol Methods
1992, 152(1):89-104.
26. Kearney JF, Radbruch A, Liesegang B, Rajewsky K: A new mouse
myeloma cell line that has lost immunoglobulin expression
but permits the construction of antibody-secreting hybrid
cell lines.  J Immunol 1979, 123(4):1548-1550.